RVD with weekly subcutaneous bortezomib minimizes neuropathy and maintains efficacy in a diverse multiple myeloma cohort

Gill, Amitoj; Jayswal, Rani; Weiss, Heidi L.; Rhodes, Jill; Hegazi, Mohamed M.; Herzig, Geoffrey P.; Herzig, Roger H.; Krem, Maxwell M.

doi:10.1016/j.clml.2019.09.349

Cited by 1 publication

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A number of RVD schedules have been proposed including RVD Classic, RVD Lite and RVD Premium Lite to minimise toxicity, which are detailed in Table 3. Higher bortezomib doses, up to 1.5–1.6 mg/m 2 are sometimes utilised in weekly protocols 37,38 to facilitate more convenient clinical visits and optimise dose intensity. If this approach is being utilised, the administration of intravenous normal saline may be helpful to minimise neurotoxicity and fatigue 39 …”

Section: What Dosing and Schedule Should I Use In A Transplant‐eligib...mentioning

confidence: 99%

Lenalidomide, bortezomib and dexamethasone induction therapy for the treatment of newly diagnosed multiple myeloma: a practical review

et al. 2022

View full text Add to dashboard Cite

Summary For patients with newly diagnosed multiple myeloma, survival outcomes continue to improve significantly: however, nearly all patients will relapse following induction treatment. Optimisation of induction therapy is essential to provide longer term disease control and the current standard of care for most patients incorporates an immunomodulatory agent and proteasome inhibitor, most commonly lenalidomide and bortezomib in combination with dexamethasone (RVD), with maintenance until progression. Historically there has been limited access to RVD as an induction strategy outside of the United States; fortunately, there is now increasing access worldwide. This review discusses the rationale for use of RVD as induction therapy and aims to provide guidance in prescribing this regimen in order to optimise efficacy while minimising the toxicities of treatment. We also highlight the increasing evidence for the utility of addition of a monoclonal antibody to the RVD backbone to deepen responses and potentially provide longer disease control.

show abstract

Section: What Dosing and Schedule Should I Use In A Transplant‐eligib...mentioning

confidence: 99%

Lenalidomide, bortezomib and dexamethasone induction therapy for the treatment of newly diagnosed multiple myeloma: a practical review

et al. 2022

View full text Add to dashboard Cite

show abstract

RVD with weekly subcutaneous bortezomib minimizes neuropathy and maintains efficacy in a diverse multiple myeloma cohort

Cited by 1 publication

References 0 publications

Lenalidomide, bortezomib and dexamethasone induction therapy for the treatment of newly diagnosed multiple myeloma: a practical review

Lenalidomide, bortezomib and dexamethasone induction therapy for the treatment of newly diagnosed multiple myeloma: a practical review

Contact Info

Product

Resources

About